Lineage extends cash runway into Q2 2028 while advancing OpRegen and new pipeline programs

Earnings Call Insights: Lineage Cell Therapeutics (LCTX) Q4 2025

MANAGEMENT VIEW

* CEO Brian Culley opened the call highlighting recent warrant exercises that have further extended the company's cash runway and announced a positive result for the initial go/no-go development milestone in the islet cell research initiative. Culley stated, "We have a great call planned highlighted by recent warrant exercises that further extend our runway and a positive result for our initial go/no-go development milestone in our islet cell research initiative."
* Culley reiterated the company's focus on advancing cell therapy applications beyond oncology, with particular emphasis on applying manufacturing success and lessons from the OpRegen program to other conditions arising from loss of critical cellular function. He described, "Our focus on replacing cells that have become dysfunctional or destroyed may fundamentally reshape many treatment and recovery paradigms."
* The CEO emphasized the expansion of clinical sites for the GAlette study, noting that Roche and Genentech opened 10 new clinical sites in the past 9 months. Culley pointed to this as a "favorable sign because this activity could support preparations for later-stage trials."
* Updates were given on the AlloSCOPE manufacturing platform, with Culley stating, "We successfully established a GMP master cell bank from which we established a GMP working cell bank and generated product that has been used in the clinic... we are confident that we can successfully repeat the process as many times as needed."
* CFO Jill Howe reported, "The reported net loss for the full year is approximately $45 million higher than in 2024, this increase is mainly due to noncash charges linked to our rising stock price over the year, which resulted in higher warrant liability."

OUTLOOK

* Lineage expects its cash and the $5.4 million in proceeds from warrants exercised in March to support planned operations into Q2 of 2028. Howe remarked, "This is a significantly higher runway than we guided to during our last call, with the biggest contributors being the $21 million in gross proceeds received from an ATM block trade in November, the warrant exercise of $5.4 million this week along with the achievement of the first $5 million milestone under our Roche collaboration."
* Management indicated the revised guidance does not include additional potential funding sources, such as further milestone payments from Roche or new partnerships.

FINANCIAL RESULTS

* Total revenues for the fourth quarter were reported at $6.6 million, representing a net increase of $3.7 million compared to Q4 2024. This was primarily due to higher collaboration revenue from the Roche agreement and a new research collaboration agreement with WDI.
* Operating expenses for the fourth quarter reached $13.2 million, up $5.2 million year-over-year, driven by increased R&D and G&A expenses. R&D expenses were $8.2 million, an increase of $4.8 million.
* For the fourth quarter, net income was $0.9 million or $0.04 per share, compared to a net loss of $3.3 million or $0.02 per share in the prior year period.
* Full-year revenues were $14.6 million, with a net loss of $63.5 million or $0.28 per share, largely attributed to noncash warrant liability remeasurement and asset impairment charges.

Q&A

* Joseph Pantginis, H.C. Wainwright: Asked about business development strategy and the translation of AlloSCOPE into partnerships. Culley responded, "What we can do, what we have the opportunity to do is to take the AlloSCOPE platform and apply it in different ways to generate a basket of assets. And then we can make some decisions that are good for the company in terms of partnering or retaining."
* Pantginis: Inquired about technical challenges in scaling islet cell production. Culley stated, "The very nature of the exploratory work is that we do not know. So we cannot predict the linearity of going from half liter to multi liter to ultimately up in the neighborhood of 80-liter or 300 liters."
* Jack Allen, Baird: Sought color on OPC1 functional measures and OpRegen data. Culley answered that the OPC1 study is designed as a safety and performance study and provided details on functional assessments, noting anecdotal reports of improvement in the first chronic patient.
* Jack Allen: Asked about the expense ramp for AlloSCOPE as reactor size increases. Culley explained, "We are able to put a relatively modest amount of capital to work to get answers as to the scalability of these lines."
* Mayank Mamtani, B. Riley Securities: Queried learnings from OpRegen and milestones for the islet initiative. Culley highlighted three core AlloSCOPE components: physical, biological, and engineering, and teased unveiling another new cell type within 3 to 6 weeks.
* Yang Chen, Raymond James: Questioned the process for implementing a new OPC1 formulation in the DOSED study. Culley described plans to switch to the new process in later study patients, aiming to "save a lot of time" versus a separate safety cohort.

SENTIMENT ANALYSIS

* Analysts demonstrated a mix of optimism and diligence, with questions focused on scalability, partnership strategy, and clinical development timelines. The sentiment was neutral to slightly positive, with some skepticism around technical and regulatory challenges.
* Management maintained a positive and confident tone during prepared remarks and Q&A. Phrases such as "we are confident" and "we believe" were frequent, indicating continued conviction in the business model and pipeline.
* Compared to the previous quarter, management's tone was more assertive regarding the company's financial position and operational runway, while analysts maintained a consistent, probing tone.

QUARTER-OVER-QUARTER COMPARISON

* The current quarter saw a significant increase in projected cash runway, from Q2 2027 to Q2 2028, driven by new warrant exercises and milestone payments.
* There was a notable expansion in clinical site openings for the OpRegen GAlette study, with 10 new sites added in the last 9 months versus 8 in the previous 6 months.
* Management provided more detailed updates on the islet cell research initiative, moving from feasibility work to achieving an internal development milestone.
* The tone from management was more confident regarding financial stability and pipeline progress, while analyst focus remained steady on scalability, partnerships, and clinical milestones.

RISKS AND CONCERNS

* Management highlighted geopolitical risks due to employees in Israel but stated that operations are continuing as planned.
* CFO Howe addressed noncash charges impacting net loss, specifically those linked to rising warrant liability and the impairment of a previously acquired asset.
* Scaling the islet cell manufacturing process remains a technical risk, with Culley acknowledging that "it is very much unexplored territory."
* Regulatory timelines and the progression of programs like OpRegen are dependent on partners such as Roche and Genentech, limiting Lineage's visibility and control over certain milestones.

FINAL TAKEAWAY

Lineage Cell Therapeutics emphasized a strengthened financial position with a cash runway into Q2 2028, supported by warrant exercises, milestone payments, and partnership revenues. Operational progress was highlighted by the expansion of OpRegen clinical sites, continued success in the AlloSCOPE manufacturing platform, and the advancement of the islet cell research initiative. Management reiterated confidence in the company’s platform and pipeline, with optionality for future growth through partnerships and new cell-based programs. Investors were encouraged to watch for additional pipeline updates and potential new cell type disclosures in the coming weeks.

Read the full Earnings Call Transcript [https://seekingalpha.com/symbol/lctx/earnings/transcripts]

MORE ON LINEAGE CELL THERAPEUTICS

* Lineage Cell Therapeutics, Inc. (LCTX) Q4 2025 Earnings Call Transcript [https://seekingalpha.com/article/4879237-lineage-cell-therapeutics-inc-lctx-q4-2025-earnings-call-transcript]
* Seeking Alpha’s Quant Rating on Lineage Cell Therapeutics [https://seekingalpha.com/symbol/LCTX/ratings/quant-ratings]
* Historical earnings data for Lineage Cell Therapeutics [https://seekingalpha.com/symbol/LCTX/earnings]
* Financial information for Lineage Cell Therapeutics [https://seekingalpha.com/symbol/LCTX/income-statement]